Azitra (AZTR) vs MetaVia (MTVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MetaVia is the larger company by market cap ($8.8 million vs $8.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AZTR | MTVA |
|---|---|---|
| Share price | $0.132 | $1.34 |
| Market cap | $8.00M | $8.83M |
| 1-day change | 0.00% | -8.22% |
| EPS (TTM) | $-0.28 | $-3.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.09 | $14.85 |
| 52-week low | $0.10 | $0.966 |
| Distance from 52-week high | -87.89% | -90.98% |
| Analyst consensus | buy | none |
| Avg. price target upside | +407.58% | +1342.54% |
| Average volume | 1.70M | 228.48K |
| Shares outstanding | 60.60M | 6.59M |
| Employees | 13 | 8 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Azitra
AZTR stock →Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S.
Healthcare · Biotechnology · 13 employees
About MetaVia
MTVA stock →MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity.
Healthcare · Biotechnology · 8 employees
AZTR vs MTVA FAQ
Which is bigger, Azitra or MetaVia?
MetaVia (MTVA) is larger, with a market capitalization of $8.83M compared with $8.00M for Azitra (AZTR).
Are Azitra and MetaVia in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.